FDA sets ac­tion date for Phath­om af­ter trace car­cino­gens led to CRL, grants As­traZeneca pri­or­i­ty re­view

Fol­low­ing a re­jec­tion in Feb­ru­ary, the FDA will take an­oth­er look at Phath­om Phar­ma­ceu­ti­cals’ gas­troe­sophageal re­flux dis­ease (GERD) treat­ment, the biotech said Mon­day.

The FDA will make its de­ci­sion on vono­prazan for ero­sive GERD by Nov. 17, Phath­om said. In Feb­ru­ary, the FDA re­ject­ed Phath­om Phar­ma­ceu­ti­cal’s ap­pli­ca­tion for vono­prazan — an acid-block­er mar­ket­ed in com­bi­na­tion with an­tibi­otics for H. py­lori as Vo­quen­za — af­ter traces of ni­trosamine im­pu­ri­ties, which are known to in­crease risk of can­cer, were found in the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER